In the MDD-BIP cross-disorder analyses, we evaluated support for a broader mood disorders phenotype. Due to the need to resolve overlapping subjects, the sample sizes and P-values differ from the numbers given above. There were 32 050 independent subjects (9238 MDD cases/8039 controls and 6998 BIP cases/7775 controls), 160 SNPs with P < 0.0001 in the MDD discovery phase and 659 SNPs in the BIP discovery phase (no SNP had P < 0.0001 for both MDD and BIP). First, in aggregate, SNPs selected from the BIP discovery phase showed evidence of replication in MDD (65 of 100 independent SNPs had logistic regression β-coefficients in the same direction in both BIP and MDD, sign test, P = 0.0018). However, the reverse comparison was near chance level (46 of 76 independent SNPs selected from MDD analyses had consistent effects in BIP, sign test P = 0.042). Second, in the combined analysis of these 819 SNPs, 15 exceeded genome-wide significance (P<5×10−8) and all were in a 248 kb interval of high LD on 3p21.1 (chr3:52 425 083–53 822 102, minimum P=5.9×10−9 at rs2535629;
